Ciccimarra, Francesco
Luxi, Nicoletta
Bellitto, Chiara
L’ Abbate, Luca
De Nardo, Pasquale
Savoldi, Alessia
Yeomans, Alison
Molokhia, Mariam
Tacconelli, Evelina
Trifirò, Gianluca http://orcid.org/0000-0003-1147-7296
Funding for this research was provided by:
Università degli Studi di Verona
Article History
Accepted: 20 April 2023
First Online: 6 May 2023
Declarations
:
: Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.
: Gianluca Trifirò has served in the past three years on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead and Amgen; he was the scientific director of a Master program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grant from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off “INSPIRE srl” which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). All the above-mentioned activities are not related to the topic of the manuscript. Mariam Molokhia has received grants previously from the International Serious Adverse Events Consortium, SAEC (not related to the topic of the manuscript). The other authors have no conflict of interest to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed equally to this work. All authors read and approved the final manuscript.
: Not applicable.